https://orcid.org/0000-0003-2549-2569
References
- Van Zandwijk N , PavlakisN , KaoSCet al. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, Phase I, open-label, dose-escalation study. Lancet Oncol.18(10), 1386–1396 (2017).
- Viart V , BergougnouxA , BoniniJet al. Transcription factors and miRNAs that regulate fetal to adult CFTR expression change are new targets for cystic fibrosis. Eur. Respir. J.45(1), 116–128 (2015).
- Sonneville F , RuffinM , CorauxCet al. microRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology. Nat. Commun.8(1), 710 (2017).
- Oglesby IK , ChotirmallSH , McElvaneyNG , GreeneCM. Regulation of cystic fibrosis transmembrane conductance regulator by microRNA-145, -223, and -494 is altered in ΔF508 cystic fibrosis airway epithelium. J. Immunol.190(7), 3354–3362 (2013).
- Lutful Kabir F , AmbalavananN , LiuGet al. microRNA-145 antagonism reverses TGF-β inhibition of F508del CFTR correction in airway epithelia. Am. J. Respir. Crit. Care Med.197(5), 632–643 (2018).
- Amato F , TomaiuoloR , NiciFet al. Exploitation of a very small peptide nucleic acid as a new inhibitor of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression. Biomed. Res. Int.2014, 610718 (2014).
- Patutina OA , MiroshnichenkoSK , MironovaNLet al. Catalytic knockdown of miR-21 by artificial ribonuclease: biological performance in tumor model. Front. Pharmacol.10, 879 (2019).
- Fernández Fernández E , Santos-CarballalB , de SantiCet al. Biopolymer-based nanoparticles for cystic fibrosis lung gene therapy studies. Materials11(1), pii: E122 (2018).
- Rupaimoole R , SlackFJ. microRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov.16(3), 203–222 (2017).
- Oglesby IK , AgrawalR , MallMA , McElvaneyNG , GreeneCM. miRNA-221 is elevated in cystic fibrosis airway epithelial cells and regulates expression of ATF6. Mol. Cell Pediatr.2(1), 1 (2015).
- Oglesby IK , VenckenSF , AgrawalRet al. miR-17 overexpression in cystic fibrosis airway epithelial cells decreases interleukin-8 production. Eur. Respir. J.46(5), 1350–1360 (2015).
- Mitash N , MuF , DonovanJEet al. Transforming growth factor-β1 selectively recruits microRNAs to the RNA-induced silencing complex and degrades CFTR mRNA under permissive conditions in human bronchial epithelial cells. Int. J. Mol. Sci.20(19), pii: E4933 (2019).
- Gill DR , HydeSC. Delivery of genes into the CF airway. Thorax69(10), 962–964 (2014).
- Craparo EF , PorsioB , SardoC , GiammonaG , CavallaroG. Pegylated polyaspartamide-polylactide-based nanoparticles penetrating cystic fibrosis artificial mucus. Biomacromolecules17(3), 767–777 (2016).
- Nafee N , ForierK , BraeckmansK , SchneiderM. Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: proof of concept, challenges and pitfalls. Eur. J. Pharm. Biopharm.124, 125–137 (2018).
- Osman G , RodriguezJ , ChanSYet al. PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy. J. Control Release285, 35–45 (2018).
- Bell SC , BarryPJ , DeBoeck Ket al. CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials. J. Cyst. Fibros.18(5), 700–707 (2019).
- de Wilde G , GeesM , MuschSet al. Identification of GLPG/ABBV-2737, a novel class of corrector, which exerts functional synergy with other CFTR modulators. Front. Pharmacol.10, 514 (2019).
- Holguin F . Triple CFTR modulator therapy for cystic fibrosis. N. Engl. J. Med.379(17), 1671–1672 (2018).